©2025 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy
Art of Drug Choice Header Bar

Editorial Feature:

The Art of Drug Choice

Wet AMD and the Latest Data

Editorially Independent content supported with advertising by Novartis and Alcon.

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Peter Kertes, MD, FRCS(C)

Show Description +

In which instances can initiating therapy with brolucizumab (Beovu, Novartis) be appropriate? Peter Kertes, MD, FRCS(C), shares the case of a patient with polypoidal choroidal vasculopathy who presented with large volumes of subretinal fluid. Which data did Dr. Kertes use to drive his decision-making—and how did this patient respond?

Posted: 8/05/2021

Keywords:

brolucizumab

•

Polypoidal choroidal vasculopathy, PCV

Up Next

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation
Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Arshad M. Khanani, MD, MA

Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient
Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient

Arshad M. Khanani, MD, MA

Switching Agents Multiple Times in a Long-term Wet AMD Patient
Switching Agents Multiple Times in a Long-term Wet AMD Patient

Lejla Vajzovic, MD

Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient
Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient

Joseph M. Coney, MD

Increasing Treatment Intervals in Wet AMD
Increasing Treatment Intervals in Wet AMD

Arshad M. Khanani, MD

A Breakthrough After Monthly Wet AMD Therapy
A Breakthrough After Monthly Wet AMD Therapy

Nikolas J.S. London, MD

Navigating Treatment Burden in Wet AMD
Navigating Treatment Burden in Wet AMD

Christina Weng, MD, MBA

Outside-the-Box Therapy for Wet AMD
Outside-the-Box Therapy for Wet AMD

Christopher G. Fuller, MD

The Value of Treatment Options in Wet AMD
The Value of Treatment Options in Wet AMD

Justus G. Garweg, MD

Switching to a New Anti-VEGF Agent Early in the Course of Therapy
Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Seenu M. Hariprasad, MD

link-arrow   Back to All Videos

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Peter Kertes, MD, FRCS(C)

In which instances can initiating therapy with brolucizumab (Beovu, Novartis) be appropriate? Peter Kertes, MD, FRCS(C), shares the case of a patient with polypoidal choroidal vasculopathy who presented with large volumes of subretinal fluid. Which data did Dr. Kertes use to drive his decision-making—and how did this patient respond?

Posted: 8/05/2021

Keywords:

brolucizumab

•

Polypoidal choroidal vasculopathy, PCV

Please log in to leave a comment.

Listen as a Podcast

nrr podcast logo

New Retina Radio

All video episodes of this series are also available as podcast episodes on New Retina Radio.

Listen Now

close-x